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E-mail address: mcguigan@cf.ac.uk (C. McGuigan)2 -b-D-Arabinouridine (AraU), the uridine analogue of the anticancer agent AraC, was synthesized and
evaluated for antiviral activity and cytotoxicity. In addition, a series of AraU monophosphate prodrugs
in the form of triester phosphoramidates (ProTides) were also synthesized and tested against a range
of viruses, leukaemia and solid tumour cell lines. Unfortunately, neither the parent compound (AraU)
nor any of its ProTides showed antiviral activity, nor potent inhibitory activity against any of the cancer
cell lines. Therefore, the metabolism of AraU phosphoramidates to release AraU monophosphate was
investigated. The results showed carboxypeptidase Y, hog liver esterase and crude CEM tumor cell
extracts to hydrolyse the ester motif of phosphoramidates with subsequent loss of the aryl group, while
molecular modelling studies suggested that the AraU L-alanine aminoacyl phosphate derivative might
not be a good substrate for the phosphoramidase enzyme Hint-1. These findings are in agreement with
the observed disappearance of intact prodrug and concomitant appearance of the corresponding phos-
phoramidate intermediate derivative in CEM cell extracts without measurable formation of araU mono-
phosphate. These findings may explain the poor antiviral/cytostatic potential of the prodrugs.
 2010 Elsevier Ltd. All rights reserved.N
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Figure 1. Structures of AraU (left) and AraC (right).1. Introduction
Cytarabine (AraC, Fig. 1) is an anticancer drug used for the treat-
ment of acute myeloid leukaemia and lymphomas, but has limited
activity against solid tumors.1 It is a prodrug that requires conver-
sion to the active triphosphate derivative by cellular kinases in or-
der to exert its cytotoxic effect. Upon the incorporation of AraCTP
into the growing DNA chain by DNA polymerases, the chain elon-
gation process is terminated.2 In this work, the uridine derivative
of AraC, that is, AraU (Fig. 1), was synthesized and investigated
for anticancer activity, and in particular its activity versus several
leukaemia cell lines was examined. AraU is in fact a metabolite
of AraC in vivo as a result of the action of cytidine deaminase,12
and this is generally regarded as a deactivation mechanism of AraC.
In parallel to the mechanism of action of AraC, AraU would most
likely have to be phosphorylated to its triphosphate derivative in
order to exert any therapeutic effect and this may be inefficient.
The phosphorylation of nucleoside analogues, in particular the first
step, is believed to be the rate-limiting process for many antiviral
and anticancer nucleosides. Thus, a series of AraU triesterll rights reserved.
.phosphoramidates (ProTides), which would by-pass the first phos-
phorylation step, were synthesized and evaluated for antiviral
activity and cytotoxic potential against a selection of leukaemia
cell lines.
The triester phosphoramidate approach is a pronucleotide ap-
proach that delivers the nucleoside analogue and carbohydrate
monophosphates into cells.3,4 In this approach, both charges of the
phosphate motif are fully masked to allow good passive membrane
diffusion. Upon entering the cell, the masking groups can be
hydrolyzed to release the nucleoside analogue/carbohydratemono-
phosphate, which, in the case of nucleosides, may be further
phosphorylated to their di- and then triphosphate derivatives. The
metabolism of phosphoramidates proceeds in fours steps; two
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2440 Y. Mehellou et al. / Bioorg. Med. Chem. 18 (2010) 2439–2446spontaneous and two involve enzymes. In this work, the two-enzy-
maticmetabolic steps of AraUphosphoramidateswere investigated.
The first enzymatic step is the hydrolysis of the ester motif of the
phosphoramidate,which in this casewas studied using carboxypep-
tidase Y that has been shown to be able to perform the hydrolysis of
the ester moiety present in phosphoramidates.5 Hog liver esterase
and crude human lymphocyte CEMcell extracts have also been used
in the hydrolysis studies. Secondly, molecular modeling studies
were carried out to investigate whether or not AraU phosphorami-
dates lacking the ester and aryl motifs may be substrates for the
Hint-1 enzyme, which is an enzyme that belongs to the phospho-
ramidase family and has been described to process such compounds
to their free monophosphates.6
2. Results and discussion
2.1. Chemistry
2.1.1. Synthesis of AraU
AraUwas synthesized in two steps (Scheme1)with thefirst reac-
tion being the formation of the 2,20-anhydrouridine (2). Thus, uri-
dine (1) and diphenyl carbonate were suspended in DMF and the
slurry was heated to 100 C.7 At this point, potassium carbonate
(K2CO3) was added and the reaction mixture was heated to 137 C.
After 1.5 h, the reaction mixture was allowed to cool to room tem-
perature and then filtered. The white solid obtained was washed
with methanol to afford the desired compound (2) in 78% yield.
The second reaction was the opening of the 2,20-anhydro bond
to generate a b-hydroxyl at the C-20. This was achieved by suspend-
ing compound 2 in water and 2 N HCl was then added and the
reaction mixture was heated to 80 C for 2 h.8 Upon neutralization
with aqueous sodium hydroxide, the solvent was removed and the
residue obtained was purified by column chromatography to give
the desired compound in 68% yield.
2.1.2. Synthesis of AraU phosphoramidates
AraU phosphoramidates were synthesised according to the
previously reported synthetic routes developed by McGuigan et
al.9–11 Aryl phosphorochloridates were prepared by the reaction
of phenyl or 1-naphthyl dichlorophosphate with the appropriate
amino acid ester hydrochlorides and tosylate salts. The obtained
phosphorochloridates were allowed to react with AraU in THF/
pyridine (7:3) and 1-methylimidazole (NMI) to give the target
phosphoramidates in moderate yields. 31P NMR investigations
of the phosphoramidates displayed two closely spaced signals,
corresponding to two diastereoisomers resulting from mixed
phosphate stereochemistry. A series of AraU phosphoramidates
bearing different ester, amino acid and aryl moieties were pre-
pared (Table 1).
2.2. Antiviral data
The araU prodrugs have been evaluated for their potential
inhibitory action against a wide variety of DNA and RNA virusesN
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Scheme 1. Reagents and conditions: (i) DMF, diphenyl carbonatein cell culture. Unfortunately, none of them showed significant
antiviral activity.2.3. Cytotoxicity data
The obtained AraU phosphoramidates as well as the parent
nucleoside (AraU) were tested for activity against a selection of
myeloid leukaemia cell lines (NB4, HL60, KG1, U937, L1210 and
CEM) (Table 2). AraU showed low (25–>500 lM) activity versus
all the cell lines tested. The best cytostatic activity was shown
against the KG1 cell line, IC50 = 24 lM. As for its phosphoramidate
derivatives they also exhibited rather poor activity against the six
tumor cell lines tested against. Notably, AraU and its phosphoram-
idates were clearly most cytostatic against NB4 and KG1 cells,
compared with the other cell lines evaluated. The reason behind
such activity profiles remains unclear.
The AraU phosphoramidate derivatives were also screened for
activity against solid tumour cell lines (A549, LoVo, PC3, MCF7)
with data being shown in Table 3. No antitumor activity was ob-
served at the maximum concentration tested (100 lM), exceptN
N
O
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, 100 C, K2CO3, 137 C, 1.5 h; (ii) H2O, HCl (2 N), 80 C, 2 h.
Table 2
Biological evaluation of AraU phosphoramidates in leukaemia cell lines (IC50 lM)
Compound Ar AA Ester NB4 HL60 KG1 U937 L1210 CEM
AraU (3) — — — 69 90 25 >100 170 >500
4 Ph D-Ala Bn 88 92 90 >100 470 313
5 Ph L-Ala Bn 38 >100 63 92 184 188
6 Ph L-Ala Me 53 >100 32 >100 >500 >500
7 Ph Gly Bn 52 >100 39 >100 256 196
8 1-Naph L-Ala iPr 77 84 67 >100 250 181
Table 3
Cytostatic evaluation of AraU phosphoramidates in solid tumour cell lines (IC50 lM)
Compound LoVo PC3 A549 MCF7
4 >100 >100 >100 50
5 >100 >100 >100 >100
6 >100 >100 >100 >100
7 >100 >100 >100 >100
8 >100 >100 >100 >100
Y. Mehellou et al. / Bioorg. Med. Chem. 18 (2010) 2439–2446 2441for (4) which was active against human breast carcinoma MCF7 at
50 lM.
The failure of AraU phosphoramidates to achieve any significant
antiviral and anticancer activity may be a result of three factors.
Firstly, AraU phosphoramidates were not metabolized (activated)
to the monophosphate derivative. Secondly, once AraU monophos-
phate has been released inside the cell, it was not phosphorylated
further to its triphosphate counterpart. Thirdly, AraU triphosphate
might not be inhibitory to the antiviral/cytostatic target enzyme
(i.e., DNA or RNA polymerase).
2.4. Metabolism of AraU phosphoramidates
The proposed metabolism of aryl phosphoramidates proceeds
in four steps to eventually release the nucleoside analogue mono-
phosphate as shown in Scheme 2.
The first metabolic step is mediated by esterase or carboxypep-
tidase enzymes, which cleave the ester motif of the aryl phosphor-
amidate molecule. This step is essential for the eventual release ofN
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Scheme 2. Postulated mechanism of actiothe nucleoside analogue monophosphate, as failure at this stage
would not lead to the release of the monophosphate. To probe
whether the ester motif of AraU phosphoramidates is cleaved off
or not, carboxypeptidase Y also known as cathepsin A, which has
been reported to catalyze this hydrolysis was used in this study.5
Phenyl-L-alanine benzyl ester AraU phosphoramidate (5) was cho-
sen to be tested. The experiment was carried out for 3 h at room
temperature, and the progress of the reaction was followed by
31P NMR (Fig. 2).
As shown in Figure 2, the phenyl-L-alanine benzyl ester phos-
phoramidate of AraU (5) appeared as two 31P NMR peaks (d 3.5–
3.9) corresponding to the two diastereoisomers (oblong highlight).
Upon the addition of cathepsin A, the compound was quickly
hydrolyzed to intermediate I (t1/2 15 min), which lacks the ester
motif (triangle highlight). However, this intermediate did not per-
sist as it was in turn quickly metabolized to intermediate ii via the
loss of the aryl motif (circle highlight). Intermediate ii was then
consistently present throughout the 3 h of the assay. This suggests
that within 3 h cathepsin A was able to hydrolyse the ester and aryl
moieties of phenyl-L-alanine benzyl ester phosphoramidate of
AraU, but not the P–N bond as no peaks corresponding to the
monophosphate were detected.
The cleavage of the P–N bond of aryl phosphoramidates is
thought to proceed via the involvement of a phosphoramidase type
enzyme.6 Hint-1 has been identified as a possible enzyme that can
cleave such a bond. Thus, in this study, Hint-1 was used for the
docking of intermediate ii to probe the possible hydrolysis of the
P–N bond to release AraU monophosphate in silico. Upon docking
(see Section 4), the analysis of the different predicted poses
showed intermediate ii as having a conformation that would allow
the interactions of the phosphate moiety with the key residues in
the catalytic site. Although the sugar hydroxyl groups did not cor-
rectly interact with the aspartic acid residues, the pyrimidine base
did fit in the hydrophobic pocket (Fig. 3). Other conformers that
retained the hydrogen bonding interactions of the sugar moiety
with the aspartic residues showed the sugar ring distorted, and
consequently, the base was pushed outside of the hydrophobic
pocket, in comparison to AMP (thin red line, Fig. 3). Thereby, the
hydrolysis of the P–N bond may not be as efficient as with purine
and ribo nucleoside analogues.is
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Figure 2. 31P NMR spectra measured at different times during hydrolysis of compound.
Figure 3. Docking of AMP (thin red line) and AraU L-alanine aminoacyl phosphate derivative.
2442 Y. Mehellou et al. / Bioorg. Med. Chem. 18 (2010) 2439–2446These findings are in agreement with the hydrolysis studies
that were performed using crude human CEM lymphocyte ex-
tracts (Fig. 4) and hog liver esterase (data not shown). Indeed,
the diastereomers of each of the prodrugs could be separated
by HPLC analysis. When the compounds were exposed to crude
CEM cell extracts for 30 and 120 min, the L-alaninyl and glycinyl
araU phosphoramidate prodrugs were converted to their corre-
sponding intermediate phosphoramidate derivatives (after release
of their ester and aryl moieties), except for compound 4 (the D-
alaninyl derivative) that remained unaltered during the incuba-
tion period (Fig. 4). Also, the speed of conversion of the prodrug
compounds 5–8 to their corresponding phosphoramidate inter-
mediate was different depending the nature of the ester/aryl part
of the prodrug. In particular, compound 5 was most efficiently
converted, followed by 6 and 8. The glycinyl prodrug 7 was theleast efficiently converted (Fig. 4). With the use of purified hog
liver esterase, it was ascertained that the metabolites that
appeared in the CEM cell extracts were indeed the expected
L-alaninyl (for 5, 6, 8) and glycinyl (for 7) intermediates of the
prodrugs (data not shown). Interestingly, whereas CEM cell
extracts did not hydrolyze the ester moiety from prodrug 4, the
hog liver esterase did, although at a much lower efficiency than
for the other prodrugs.
As the application of the phosphoramidate technology to widely
diverse ribo- and deoxyribonucleoside analogues has mostly led to
improvements in biological activity.13–18 In this case, its applica-
tion to an arabinonucleoside did not improve the biological activ-
ity. The type of the nucleoside analogue seems to affect the
cleavage of the P–N bond and thus the outcome of the use of such
a pronucleotide technology.
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Figure 4. Conversion of prodrugs 4–8 in the presence of human T-lymphocyte CEM cell extracts. Panel A. Disappearance (hydrolysis) of prodrug. The individual
diastereomers are represented by the black and dashed bars. The levels of the parent prodrug molecules and their conversion products are given as percentage of total
amounts of parent compound and metabolites. Panel B. Appearance of the aminoacyl phosphoramidate intermediates (expressed as area under the curve).
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A series of AraU phosphoramidates were synthesized and inves-
tigated for antiviral activity and for cytotoxicity versus six leukae-
mia cell lines and four solid tumour cell lines. Unfortunately, none
of the phosphoramidates or their parent nucleoside (AraU) showed
significant activity. Metabolic assays using carboxypeptidase Y and
hog liver esterase showed the ability of these enzymes tometabolize
the estermotif of AraU phosphoramidates, with subsequent sponta-
neous phenyl loss. Molecular modelling studies suggested AraU L-
alanine aminoacyl phosphate may not to be a good substrate for
Hint1. In crude CEMcell extracts, formation of the phosphoramidate
intermediate was seen for the L-alaninyl and glycinyl prodrugs, but
not for the D-alaninyl prodrug. No formation of AraU monophos-
phate was observed. Thus both hydrolysis studies and docking sug-
gest that the efficiency of the P–N bond cleavage to release AraU
monophosphate might be a contributor to the poor cytotoxic activ-
ity of AraU ProTides. Taken together, these results suggest that the
poor cytostatic activities of AraU phosphoramidates could be a re-
sult of inefficient P–N cleavage, though poor phosphorylation to
the di- and triphosphates could also be reasons for poor biological
activity. This study does suggest that phosphoramidate ProTides
may have limited efficacy for arabino nucleosides, although the
exact scope of this conclusion needs confirmation.4. Experimental
4.1. General
All experiments involving water-sensitive compounds were
carried out under dry conditions. The solvents used were dry and
used as purchased from Aldrich. All the glassware was oven-dried
at 130 C for several hours and allowed to cool under a steam of dry
nitrogen.
Thin-Layer Chromatography (TLC) was performed using pre-
coated, aluminium-backed silica gel plates (60 F-54, 0.2 mm thick-
ness; supplied by E Merck AG, Darmstad, Germany). Visualisation
of the plates was achieved using an ultra-violet (UV) lamp.
Glass columns were slurry-packed in the appropriate eluant un-
der pressure with silica gel, 60A, 40–60 lm, (Phase Separations Ltd,
Deeside, Clwyd, UK). Samples were applied as a concentrated solu-
tion in the same eluant or pre-absorbed on silica gel. Fractions con-
taining the product were identified by TLC, pooled and the solvent
was removed in vacuo.
1H, 13C, 31P NMR spectra were recorded on a Bruker Avance
500 MHz spectrometer and autocalibrated to the deuterated sol-
vent reference peak. The following abbreviations are used in the
assignment of NMR signals: s (singlet), d (doublet), t (triplet), q
(quartet), m (multiplet).
2444 Y. Mehellou et al. / Bioorg. Med. Chem. 18 (2010) 2439–2446HPLC analytical investigations were conducted on a Varian Pro-
star instrument (LC work station, Varian prostar 355 LC detector)
using a Polaris C18-A 10 lm column; eluant was performed using
a mobile phase consisting of a water/acetonitrile gradient.
Electrospray mass spectra were obtained using a Waters LCT
time of flight (TOF) mass spectrometer coupled to a Waters
M600 HPLC pump. Data was collected in the continuummode over
the mass range 100–2000 amu and processed using Masslynx 4.1
software.
4.2. Chemistry
4.2.1. 1-((2R,4S,5R)-3,4-Anhydro-5-(hydroxymethyl)tetrahydro-
furan-2-yl)pyrimidin-4(1H)-one (2)
Uridine (5.00 g, 20.47 mmol) and diphenyl carbonate (4.88 g,
22.80 mmol) were suspended in DMF (40 mL). The slurry was
heated to 100 C and sodium bicarbonate (150 mg) was then added
and the reaction mixture was heated up to 137 C for 1.5 h. After
completion, the reaction was cooled down to room temperature,
filtered and washed with methanol (60 mL). Following drying un-
der vacuum for 3 h the title compound obtained as a white solid
in 78% yield (3.60 g). 1H NMR (DMSO-d6): d 7.83 (1H, d, J = 8.1
Hz, H-6), 6.31 (1H, m, H-10), 5.90 (1H, d, J = 8.1 Hz, H-5), 5.83
(1H, s, H-30), 5.21 (1H, s, H-40), 5.06 (1H, s, H-50), 4.37 (1H, s, 50-
OH), 4.09 (1H, s, 30-OH), 3.15–3.24 (2H, m, H-20). 13C NMR
(DMSO-d6): d 171.32 (CO), 159.79 (CO), 136.84 (C6), 108.56 (C5),
89.99 (C10), 89.18 (C20), 88.74 (C40), 74.72 (C30), 74.79 (C50).
4.2.2. 1-((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetra-
hydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (3)
Compound 2 (3.50 g, 15.47 mmol) in 20 mL of 2 N HCl was
heated to 80 C for 2 h. The reaction mixture was cooled down
and neutralized to pH 7 with sodium hydroxide. The solvent
was removed and the crude was purified by column chromatogra-
phy employing 15% methanol in DCM as an eluant. Pooling and
evaporation of the appropriate fractions gave the title compound
(2.55 g, 68% yield) as a white solid. 1H NMR (DMSO-d6): d 11.24
(1H, br s, NH), 7.64 (1H, d, H-6, J = 8.1), 5.98 (1H, m, H-10), 5.63
(1H, m, 20-OH), 5.57 (1H, d, J = 8.1 Hz, H-5), 5.53 (1H, m, 30-OH),
5.10 (1H, s, 50-OH), 4.04 (1H, m, H-20), 3.92 (1H, m, H-30), 3.75
(1H, m, H-40), 3.56–3.62 (2H, m, H-50). 13C NMR (DMSO-d6): d
163.41 (CO), 150.40 (CO), 142.28 (C-6), 99.86 (C-5), 85.05 (C-10),
84.59 (C-40), 75.28 (C-30), 75.13 (C-20), 60.67 (C-50).
4.3. Standard procedure for the synthesis of phosphoramidates
AraU (1 equiv) was dissolved in 10 mL of THF/pyridine (7/3) un-
der argon. 1-Methylimidazole (NMI, 5 equiv) was added to the
reaction flask and this was followed by the addition of the appro-
priate phosphorochloridate (3 equiv) and the mixture was stirred
at room temperature for 16 h. Upon the removal of the solvent,
the crude was purified by column chromatography (CH2Cl2/CH3OH
95/5) and then preparative HPLC to give the desired product as a
white solid.
4.3.1. Synthesis of arabinouridine-50-[phenyl-(benzoxy-L-alan-
inyl)]-phosphate (5)
Prepared using AraU (0.20 g, 0.82 mmol), NMI (0.33 mL,
4.09 mmol), phenyl-(benzoxy-L-alaninyl)-phosphorochloridate
(0.87 g, 2.46 mmol). The desired product was obtained as a white
solid (150.0 mg, 33%). 31P NMR (MeOD, 202 MHz): d 3.76, 3.69. 1H
NMR (MeOD, 500 MHz): d 7.74 (1H, d, J = 8 Hz, H-6), 7.37–7.17
(10H, m, Ph, Ph), 6.19, 6.20 (1H, 2d, J = 4.0 Hz, H-10), 5.62, 5.56
(1H, 2d, J = 8.0 Hz, H-5), 5.17–5.12 (2H, m, CH2Ph), 4.44–4.30 (2H,
m, H-50), 4.25–4.22 (1H, m, H-20), 4.14–4.02 (3H, m, H-30, H-40,
CHNH), 1.38, 1.37 (3H, 2d, J = 8.0, 7.5 Hz, CH3CH). 13C NMR (MeOD,125 MHz): d 20.45, 20.56 (2d, J = 7.5 Hz, CH3CH), 51.69, 51.79
(CHNH), 67.23, 67.45 (2d, J = 5.0 Hz, C-500), 68.03, 68.06 (CH2Ph),
76.74 (C-20), 77.52, 77.74 (C-30), 84.18, 84.33 (2d, J = 7.5 Hz, C-40),
87.87 (C-10), 101.33 (C-5), 121.46, 121.51, 121.55, 126.21, 126.24,
129.29, 129.33, 129.40, 129.66, 129.98, 130.85, 130.86, 131.20
(Ph), 137.25 (ipso Ph), 144.25, 144.36 (C-6), 152.14, 152.26 (C-2),
166.42 (C-4), 174.75, 174.92 (2d, J = 5 Hz, C = O). MS (ES+) m/e:
584.4 (MNa+, 100%); Accurate mass: C25H28N3O10NaP required
584.1410, found 584.1418. HPLCb (H2O/CH3CN from 100/0 to 0/
100 in 20 min): tR 13.31, 13.41 min.
4.3.2. Synthesis of arabinouridine-50-[phenyl-(methoxy-L-alan-
inyl)]-phosphate (6)
Prepared using AraU (0.20 g, 0.82 mmol), NMI (0.33 mL,
4.09 mmol), phenyl-(methoxy-L-alaninyl)-phosphorochloridate
(0.68 g, 2.46 mmol). The desired product was obtained as a white
solid (110.0 mg, 28%). 31P NMR (MeOD, 202 MHz): d 3.77, 3.70.
1H NMR (MeOD, 500 MHz): d 7.77, 7.75 (1H, 2d, J = 8 Hz, H-6),
7.40–7.19 (5H, m, Ph), 6.21, 6.20 (1H, 2d, J = 4.0 Hz, H-10), 5.64,
5.60 (1H, 2d, J = 8.0 Hz, H-5), 4.46–4.31 (2H, m, H-50), 4.25–4.22
(1H, m, H-20), 4.16–4.09 (2H, m, H-30, H-40), 4.04–3.98 (2H, m,
CHNH), 3.70 (3H, s, CH3O), 1.38 (1.5H, dd, J = 7.5, 0.5 Hz, CH3CH
one d.i.), 1.36 (1.5H, dd, J = 7.0, 0.5 Hz, CH3CH one d.i.). 13C NMR
(MeOD, 125 MHz): d 20.44, 20.55 (2d, J = 7.5 Hz, CH3CH), 51.52,
51.63 (CHNH), 52.87, 52.90 (CH3O), 67.23, 67.35 (2d, J = 6.25 Hz,
C-50), 76.74 (C-20), 77.55, 77.70 (C-30), 84.31, 84.38 (2d, J = 7.5 Hz,
C-40), 87.86, 87.88 (C-10), 101.29 (C-5), 121.48, 126.23, 130.85,
131.18 (Ph), 144.29, 144.37 (C-6), 152.17, 152.26 (C-2), 166.42
(C-4), 175.42, 175.59 (2d, J = 5.0 Hz, C@O). MS (ES+) m/e: 508.2
(MNa+, 100%); Accurate mass: C19H24N3O10NaP required
508.1097, found 508.1107. HPLCb (H2O/CH3CN from 100/0 to 0/
100 in 20 min): tR 10.41, 10.53 min.
4.3.3. Synthesis of arabinouridine-50-[1-naphthyl-(isopropoxy-
L-alaninyl)]-phosphate (8)
Prepared using AraU (0.20 g, 0.82 mmol), NMI (0.33 mL,
4.09 mmol), naphthyl-(isopropoxy-L-alaninyl)-phosphorochlori-
date (0.87 g, 2.46 mmol). The desired product was obtained as a
white solid (102.5 mg, 22%). 31P NMR (MeOD, 202 MHz): d 4.24,
4.17. 1H NMR (MeOD, 500 MHz): 8.19–7.37 (8H, m, Naph, H-6),
6.14 (1H, d, J = 4.0 Hz, H-10), 5.49, 5.39 (1H, 2d, J = 8.0 Hz, H-5),
4.94–4.85 (1H, m, CHCH3), 4.48–4.32 (2H, m, H-50), 4.18–4.15
(1H, m, H-20), 4.12–4.04 (2H, m, H-30, H-40) 3.99–3.92 (2H, m,
CHNH), 1.29 (3H, dd, J = 7.0, 0.5 Hz, CH3CH), 1.17–1.11 (6H, m,
(CH3)2CH). 13C NMR (MeOD, 125 MHz): d 20.47, 20.60 (2d, J = 7.5,
6.25 Hz, CH3CH), 21.91, 21.95, 21.99 ((CH3)2CH), 51.83, 51.90
(CHNH), 67.42, 67.59 (2d, J = 5.0, 6.25 Hz, C-50), 70.22, 70.25
((CH3)2CH), 76.70 (C-20), 77.61, 77.77 (C-30), 84.34, 84.41 (2d,
J = 8.75 Hz, C-40), 87.87 (C-10), 101.21 (C-5), 116.20, 116.22,
116.28, 116.31, 122.73, 122.85, 125.99, 126.58, 127.45, 127.52,
127.83, 127.91, 128.91 (Naph), 136.33 (ipso Naph), 144.22,
144.36 (C-6), 152.21 (C-2), 166.32 (C-4), 174.48, 174.72 (C@O).
MS (ES+) m/e: 586.4 (MNa+, 100%); Accurate mass: C25H30N3O10-
NaP required 586.1567, found 586.1571. HPLC (H2O/CH3CN from
100/0 to 0/100 in 20 min): tR 13.43, 13.60 min.
4.3.4. Synthesis of arabinouridine-50-[phenyl-(benzoxy-D-alan-
inyl)]-phosphate (4)
Prepared using AraU (0.20 g, 0.82 mmol), NMI (0.33 mL,
4.09 mmol), phenyl-(benzoxy-D-alaninyl)-phosphorochloridate
(0.87 g, 2.46 mmol). The desired product was obtained as a white
solid (140.0 mg, 30%). 31P NMR (MeOD, 202 MHz): d 4.02, 3.50.
1H NMR (MeOD, 500 MHz): d 7.77, 7.71 (1H, 2d, J = 8.0 Hz, H-6),
7.37–7.17 (10H, m, Ph, Ph), 6.20, 6.18 (1H, 2d, J = 4.0 Hz, H-10),
5.61, 5.56 (1H, 2d, J = 8.0 Hz, H-5), 5.19–5.12 (2H, m, CH2Ph),
4.37–4.27 (2H, m, H-50), 4.23–4.22 (1H, m, H-20), 4.11–4.00 (3H,
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1.36 (1.5H, dd, J = 7.0, 0.5 Hz, CH3CH one d.i.). 13C NMR (MeOD,
125 MHz): d 20.45, 20.50 (CH3CH), 51.62, 51.76 (CHNH), 67.09,
67.43 (2d, J = 5.0 Hz, C-50), 68.02, 68.07 (CH2Ph), 76.71, 76.76 (C-
20), 77.43, 77.64 (C-30), 84.15, 84.30 (2d, J = 8.75 Hz, C-40), 87.79
(C-10), 101.27, 101.30 (C-5), 121.43, 121.47, 121.51, 121.55,
126.21, 129.31, 129.40, 129.64, 129.71, 129.73, 130.85, 131.17
(Ph), 137.25 (ipso Ph), 144.27, 144.40 (C-6), 152.17, 152.26 (C-2),
166.44 (C-4), 174.78, 174.94 (2d, J = 5.0 Hz, C@O). MS (ES+) m/e:
584.3 (MNa+, 100%); Accurate mass: C25H28N3O10NaP required
584.1410, found 584.1395. HPLC (H2O/CH3CN from 100/0 to 0/
100 in 20 min): tR 13.43 min.4.3.5. Synthesis of arabinouridine-50-[phenyl-(benzoxy-glycinyl)]-
phosphate (7)
Prepared using AraU (0.20 g, 0.82 mmol), NMI (0.33 mL,
4.09 mmol), phenyl-(benzoxy-glycinyl)-phosphorochloridate
(0.83 g, 2.46 mmol). The desired product was obtained as a white
solid (168.0 mg, 37%). 31P NMR (MeOD, 202 MHz): d 5.01, 4.78.
1H NMR (MeOD, 500 MHz): d 7.76, 7.72 (1H, 2d, J = 8 Hz, H-6),
7.37–7.17 (10H, m, Ph, Ph), 6.20, 6.19 (1H, 2d, J = 4.0 Hz, H-10),
5.61, 5.57 (1H, 2d, J = 8.0 Hz, H-5), 5.19–5.14 (2H, m, CH2Ph),
4.46–4.34 (2H, m, H-50), 4.25–4.22 (1H, m, H-20), 4.13–4.08 (3H,
m, H-30, H-40), 3.85–3.81 (2H, m, CH2NH). 13C NMR (MeOD,
125 MHz): d 43.95, 43.97 (CH2NH) 67.21, 67.49 (2d, J = 6.25,
5.0 Hz, C-50), 68.03 (CH2Ph), 76.75 (C-20), 77.47, 77.66 (C-30),
84.19, 84.33 (2d, J = 7.5 Hz, C-40), 87.79 (C-10), 101.32 (C-5),
121.49, 121.53, 126.27, 129.39, 129.41, 129.65, 129.70, 129.72,
129.74, 129.76, 129.98, 130.88 (Ph), 137.17 (ipso Ph), 144.26,
144.36 (C-6), 152.12, 152.24 (C-2), 166.40 (C-4), 172.31, 172.35
(C@O). MS (ES+) m/e: 570.2 (MNa+, 100%); Accurate mass:
C24H26N3O10NaP required 570.1254, found 570.1262. HPLC (H2O/
CH3CN from 100/0 to 0/100 in 20 min): tR 12.77, 12.89 min.
4.4. Leukaemia cell line assays
AraU phosphoramidates were evaluated against six myeloid cell
types (NB4, HL60, KG1, U937, CEM, L1210) in vitro. Inhibitory con-
centrations (IC50) at which 50% of the cell growth was reduced (cell
counting assay (CEM, L1210) using a Coulter Counter) or no longer
viable (calculated using an MTS assay) were determined. Cells
were treated with AraU and its ‘ProTides’ at concentrations be-
tween 100 lM and 0.02 lM by serial dilutions and incubated for
72 h at 37 C, 5% CO2 in a final volume of 90 lL. Twenty microliters
of MTS reagent (Promega UK Ltd, Southampton, Hants) was added
to the tumor cell cultures (NB4, HL60, KG1 and U937) and the reac-
tion incubated for a further 4 h at 37 C, 5% CO2. The absorbance of
the reaction after this time was read by spectrophotometry at
490 nm and the percentage of viable cells calculated relative to un-
treated control cells in the same assay.
4.5. Solid tumour cell line assays
Anti-tumour evaluation in MCF7, LoVo, A549 and PC3 cell lines
was performed using MTT assay. Protides were prepared as 0.1–
100 mM stock solutions dissolved in DMSO and stored at 20 C.
Cells were seeded into 96-well microtitre plates at a density of
5  103 cells per well and allowed 24 h to adhere. Decimal protide
dilutions were prepared in medium immediately prior to each as-
say (final concentration 0.1–100 lM). Following 96 h protide expo-
sure at 37 C, 5% CO2, MTT reagent (Sigma Aldrich) was added to
each well (final concentration 0.5 mg/mL). Incubation at 37 C for
4 h allowed reduction of MTT by viable cells to an insoluble forma-
zan product. MTT was removed and formazan solubilised by addi-
tion of 10% Triton X-100 in PBS. Absorbance was read on a TecanSunrise plate reader at 540 nm as a measure of cell viability; thus
inhibition relative to control was determined (IC50).
4.6. Enzymatic carboxypeptidase Y assay
The phosphoramidate prodrug (5 mg) was dissolved in acetone-
d6 (150 lL), and TRIZMA buffer pH 7.6 (300 lL) was added. The
resulting cloudy solution was placed in a NMR tube and a 31P
NMR experiment at 25 C was recorded as the blank experiment.
The frozen enzyme Carboxypeptidase Y [EC 3.4.16.1] (0.3 mg),
left out to reach room temperature (at least 20 min), was then sol-
ubilised in TRIZMA (150 lL) and added to the solution of phos-
phoramidate in the NMR tube. Immediately after, the tube was
placed in the NMRmachine, which was set to run a 31P NMR exper-
iment (64 scans) every 10 min for 3 h at 25 C. Data were processed
and analysed with Bruker TOPSPIN 2.1 program.
4.7. Molecular modelling
All molecular modelling studies were performed on a MacPro
dual 2.66 GHz Xeon running Ubuntu 8 using Molecular Operating
Environment (MOE) 2008.10 and FlexX (Biosolveit FlexX 3; Biosol-
veIT GmbH An der Ziegelei 75, 53757 Sankt Augustin, Germany;
http://www.biosolveit.de/flexx).
Hydrogen atoms were added to the crystal structure (PDB
code: 1KPF) and minimised with MOE until a gradient of
0.05 kcal mol1 Å1 was reached, using the MMFF94x forcefield.
The partial charges were automatically calculated. Docking exper-
iments were carried out using the MOE GUI of FlexX implemented
in MOE. AraU analogues were built in MOE and minimised before
the docking.
4.8. Antiviral assays
The compounds were evaluated against the following viruses:
herpes simplex virus type 1 (HSV-1) strain KOS, thymidine ki-
nase-deficient (TK-) HSV-1 KOS strain resistant to ACV (ACVr), her-
pes simplex virus type 2 (HSV-2) strain G, vaccinia virus Lederle
strain, respiratory syncytial virus (RSV) strain Long, vesicular sto-
matitis virus (VSV), Coxsackie B4, Parainfluenza 3, Reovirus-1,
Sindbis, Punta Toro, influenza virus type A (H1N1, H3N2) and type
B and feline corona virus. The antiviral, other than anti-HIV, assays
were based on inhibition of virus-induced cytopathicity in human
embryonic lung (HEL) fibroblasts, African green monkey cells
(Vero), human epithelial cervix carcinoma cells (HeLa), Crandel fe-
line kidney cells (CFKC) or Madin-Darby canine kidney cells
(MDCK). Briefly, confluent cell cultures in microtiter 96-well plates
were inoculated with 100 CCID50 of virus (1 CCID50 being the virus
dose to infect 50% of the cell cultures). After a 1–2 h adsorption
period, residual virus was removed, and the cell cultures were
incubated in the presence of varying concentrations of the test
compounds. Viral cytopathicity was recorded as soon as it reached
completion in the control virus-infected cell cultures that were not
treated with the test compounds. Antiviral activity was expressed
as the EC50 or compound concentration required to reduce virus-
induced cytopathicity by 50%. Cytotoxicity of the test compounds
was expressed as the minimum cytotoxic concentration (MCC) or
the compound concentration that caused a microscopically detect-
able alteration of cell morphology.
To examine inhibition of HIV-induced cytopathicity in CEM
cells, human CEM cell cultures (3  105 cells mL1) were infected
with 100 CCID50 HIV-1(IIIB) or HIV-2(ROD) per mL and seeded in
96-well (200 lL/well) microtiter plates, containing appropriate
dilutions of the test compounds. After 4 days of incubation at
37 C, syncytia formation was examined microscopically in the
CEM cell cultures. EC50 values were determined as described above.
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CC50, or the compound concentration required to reduce cell prolif-
eration by 50% relative to the number of cells in the untreated con-
trols. CC50 values were estimated from graphic plots of the number
of cells (percentage of control) as a function of the concentration of
the test compounds.
4.9. Prodrug conversion studies in the presence of crude cell
extracts
CEM cell extracts were prepared from 20  106 exponentially
growing cells, suspended in 1 ml PBS upon sonication (to destroy
the integrity of the cells), and subsequent centrifugation (to re-
move the cell debris). Six hundred microliters incubation medium
(containing 200 ll cell extract, 200 ll PBS and 200 ll test com-
pound at 300 lM in 15% DMSO) was prepared and kept at 37 C
for 0, 30 or 120 min. At each time point 100 ll was withdrawn
from the incubation medium and added to 200 ll ice-cold metha-
nol 100% (final concentration: 66%). After 10 min at 4 C, the reac-
tion mixtures were centrifuged at 13,000 rpm for 10 min and
150 ll of the supernatants were analyzed by reverse phase HPLC.
The retention times for both enantiomers of 4 were 18.3 and
18.4 min, for 5 the tR were 18.3 and 18.4 min, for 6 the tR were
15.0 and 15.2 min, for 7 the tR were 17.7 and 17.8 min and for 8
the tR were 18.5 and 18.7 min. Separation of the parent com-
pounds and the conversion products was performed on a reverse
phase (Lichrospher-60 RP-select B) column (Merck, Darmstadt,
Germany) using following gradient: 2 min 2% acetonitrile (Buffer
A); 8 min linear gradient to 20% Buffer A + 80% Buffer B (50 mM
NaH2PO4 + 5 mM heptane sulfonic acid); 2 min linear gradient to
25% Buffer A and 75% Buffer B; 2 min linear gradient to 35% Buffer
A + 65% Buffer B; 8 min linear gradient to 50% Buffer A and 50%
Buffer B; 10 min isocratic flow; 5 min linear gradient to 2% Buffer
A + 98% Buffer B; 5 min equilibration by 2% Buffer A + 98% Buffer B.
4.10. Hog liver carboxyesterase studies
The conversion of the prodrugs by hog liver esterase (Boehrin-
ger, Mannheim, Germany) (5% in TrisHCl 25 mM, MgCl2 10 mM,
pH 7.6) was analysed by Anion Exchange HPLC. The retention times
for the L- and D-alaninyl phosphoramidate intermediates were
9.36–9.40 min and for the glycinyl phosphoramidate intermediateof 7was 9.52 min. Following anion exchange (Column Partisphere-
Sax, Whatman, Maidstone, UK) gradient was used: 5 min Buffer A
(5 mM NH4H2PO4, pH 5.0), 15 min linear gradient to Buffer B
(300 mM NH4H2PO4, pH 5.0), 20 min at Buffer B, 5 min linear gra-
dient to Buffer A, 5 min Buffer A (equilibration).
Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.bmc.2010.02.059.
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